Introduction
History
TLIF
MITLIF
Technique
Materials and methods
Search method and inclusion criteria
Statistical methods for the meta-analysis
Description and interpretation of the forest plots
Results
Search results
Author | Zhang et al. [14] | Yang et al. [15] | Tschugg et al. [16] | Kulkarni et al. [17] | Hey et al. [18] | Adogwa et al. [19] |
Year of publication | 2017 | 2017 | 2017 | 2016 | 2015 | 2015 |
Study design | Retrospective | RCT | Retrospective | Prospective | Prospective | Prospective |
Level of evidence | – | II | – | – | – | – |
Number of patients | 107 (M = 48, O = 59) | 41 (MI = 21, O = 20) | 67 (MI = 19, O = 48) | 61 (MI = 36, O = 25) | 50 (MI = 25, O = 25) | 148 (MI = 40, O = 108) |
Follow-up (months) | – | Minimum 24 months | 3 months | 36.5 months (mean follow-up) | Minimum 24 months | 24 months |
Mean patient age (years) | MI: 55.7, O: 59.7 | MI: 63.5, O: 58.0 | MI: 63.9, O: 64.4 | MI: 51.55, O: 50.4 | MI: 43.6, O: 44.4 | MI: 56.62, O: 56.12 |
Gender (m/f) | MI: 24/24, O: 32/27 | MI: 7/14, O: 8/12 | MI: 8/11, O: 16/32 | MI: 10/26, O: 11/14 | MI: 13/12, O: 13/12 | MI: 20/20, O: 47/61 |
Diagnosis | -DDD (MI/O: 40/47) -Spinal instability (MI/O: 8/12) | -Spinal stenosis (MI/O: 11/9) -Olisthesis (MI/O: 5/6) -Disc herniation with segmental instability (MI/O: 5/5) | -Lumbar spondylodiscitis | -Olisthesis (MI/O: 30/12) -Disc herniation (MI/O: 5/11) -Lumbar canal stenosis (MI/O: 1/2) | -DDD: (MI/O: 2/2) -Prolapsed intervertebral discs (MI/O: 12/12) -Spinal stenosis (MI/O: 3/3) -Spondylolisthesis (MI/O: 7/7) | -DDD: (MI/O: 27/81) -Olisthesis (MI/O: 29/78) |
Outcomes | Operative time (min), LOS (days), HBL, TBL, PBL | VAS (back, leg), ODI, operative time (min), interbody fusion (grade I—Bridwell criteria), HBL, TBL | Intraoperative blood transfusion, operative time, LOS, postoperative complications | VAS (back, leg), ODI, LOS, operative time, radiation exposure, QCRP, blood loss | Operation time, EBL, drop in hemoglobin on the first postoperative day, LOS, duration to ambulation, ODI, cage height and fusion rates, complications | VAS (back, leg), ODI, complications |
Author | Yee et al. [20] | Terman et al. [21] | Wong et al. [22] | Sulaiman et al. [13] | Singh et al. [23] | Gu et al. [24] |
Year of publication | 2014 | 2014 | 2014 | 2014 | 2014 | 2014 |
Study design | Retrospective | Retrospective | Prospective | Retrospective | Prospective | Prospective |
Level of evidence | – | – | – | – | – | – |
Number of patients | 68 (MI = 52, O = 16) | 74 (MI = 53, O = 21) | 198 (MI = 144, O = 54) | 68 (MI = 57, O = 11) | 66 (MI = 33, O = 33) | 82 (MI = 44, O = 38) |
Follow-up (months) | Minimum 6 months | 30 months (mean follow-up) | 45 months (mean follow-up) | – | – | 20 months (mean follow-up) |
Mean age (years)I | MI: 47.9, O: 56.1 | MI: 52.4, O: 58.2 | MI: 61, O: 58 | MI: 61.1, O: 56.4 | MI: 51.67, O: 49.85 | MI: 66.4, O: 64.1 |
Gender (m/f) | MI: 24/28, O: 5/11 | MI: 24/29, 0: 13/8 | MI: 61/83, O: 25/29 | MI: 17/40, O: 4/7 | MI: 23/10, O: 21/12 | MI: 19/25, O: 15/23 |
Diagnosis | -DDD (MI/O: 17/2) -Herniated disc (7/0) -Olisthesis (MI/O: 24/12) -Stenosis (MI/O: 4/2) | -DDD or spondylosis (MI/O: 10/5) -Herniated disc (MI/O: 3/0) -Olisthesis (MI/O: 32/14) -Stenosis (MI/O: 8/2) | -Olisthesis +/− tilt with stenosis -Post-laminectomy instability with stenosis -DDD | Grade 1–2 degenerative olisthesis | -DDD (MI/O: 19/19) -Olisthesis (MI/O: 6/9) -Spinal stenosis (MI/O: 8/5) | -DDD (MI/O: 15/11) -Two-level lumbar stenosis (MI/O: 18/14) -Lumbar stenosis with segmental instability (MI/O: 11/13) |
Outcomes | Development of symptomatic ASD (defined by: 1. new back and/or leg pain, 2. imaging findings adjacent to original surgical level, 3. decision to treat) | VAS, ODI, EBL, LOS; in obese patients | Blood loss, operative time, VAS, ODI, LOS, inpatient institutional costs, radiation exposure, fusion rates, segmental lordosis correction, complications and revisions | Operation time, EBL, perioperative complications, LOS, VAS, ODI, hospital costs | Operation time, LOS, EBL, anesthesia time (minutes), VAS, hospital costs/ payment amount | Operation time, intraoperative blood loss, transfusion volume, LOS, radiation exposure time, VAS, ODI, fusion rates, complications |
Author | Brodano et al. [25] | Seng et al. [26] | Cheng et al. [27] | Lau et al. [28] | Rodriguez-Vela et al. [29] | Parker et al. [30] |
Year of publication | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 |
Study design | Retrospective | Retrospective | Retrospective | Retrospective | Prospective | Prospective |
Level of evidence | – | III | – | – | – | – |
Number of patients | 64 (MI = 30, O = 34) | 80 (MI = 40, O = 40) | 75 (MI = 50, O = 25) | 127 (MI = 78, O = 49) | 41 (MI = 21, O = 20) | 100 (MI = 50, O = 50) |
Follow-up (months) | 23 months (mean follow-up) | 60 months | 60 months (average follow-up) | – | Minimum 36 months | 24 months |
Mean age (years) | MI: 46, O: 51 | MI: 56.6, O: 56.8 | MI: 53.7, O:54.3 | -Class I obesity (BMI 30.0–34.9 kg/m2): MI: 52.5, O:54.1 -Class II obesity (BMI 35.0–39.9 kg/m2): MI: 50.5, O: 57.4 -Class III obesity (BMI > 40): MI: 53.5, O: 59.4 | MI: 41.81, O: 43.15 | MI: 53.5, O: 52.6 |
Gender (m/f) | MI: 18/12, O: 20/14 | MI: 7/33, O: 7/33 | MI: 27/23, O: 14/11 | MI: 38/40, O: 23/26 | MI: 14/7, O: 13/7 | MI: 16/34, O: 18/32 |
Diagnosis | -DDD -Grade I degenerative olisthesis | -Olisthesis (MI/O: 31/33) -DDD with spinal stenosis (MI/O: 9/7) | -Spondylosis (MI/O: 28/12) -Olisthesis (MI/O: 27/14) -> Grades I and II (MI/O: 27/12) -> Grades III and IV (MI/O: 0/2) -Foraminal stenosis (MI/O: 25/10) | -Olisthesis (MI/O: 50/25) -DDD alone (MI/O: 12/12) -DDD with stenosis (MI/O: 9/11) -DDD with deformity (MI/O: 1/0) -DDD with disc herniation (MI/O: 6/1) | -DDD | -Grade I degenerative olisthesis |
Outcomes | VAS, ODI, TBL, LOS, operation time, complications | VAS, ODI, radiation exposure time, operative time, LOS, complication rate, fusion rates (Bridwell criteria) | Postoperative pain medication, functional ability, VAS, EBL, operative time, LOS, fusion rates, complications, inpatient hospitalization costs | EBL, complications (total, intraoperative and 30-day postoperative), LOS | VAS, NASS, ODI, SF-36 Health Survey, postoperative complications | VAS, ODI, SF-36 Health Survey, operative time, EBL, complications, LOS, narcotic independence, return to work, hospital costs (direct and indirect) |
Author | Adogwa et al. [31] | Wang et al. [32] | Pelton et al. [33] | Lee et al. [6] | Parker et al. [34] | Lau et al. [35] |
Year of publication | 2012 | 2012 | 2012 | 2012 | 2012 | 2010 |
Study design | Prospective | Prospective | Prospective | Prospective | Prospective | Retrospective |
Level of evidence | – | – | – | – | – | – |
Number of patients | 21 (MI = 14, O = 7) | 81 (MI = 42, O = 39) | 66 (MI = 33, O = 33) | 144 (MI = 72, O = 72) | 30 (MI = 15, O = 15) | 22 (MI = 10, O = 12) |
Follow-up (months) | 24 months | 36 months (mean follow-up) | – | 24 months | 24 months | Minimum 12 months |
Mean age (years) | MI: 48.14, O: 47.28 | MI: 56.4, O: 54.2 | MI:51.67, O: 49.85 | MI: 52.2, O: 56.6 | MI: 50.8, O: 49.7 | MI: 46.9, O: 56.9 |
Gender (m/f) | MI: 4/10, O: 3/4 | MI: 13/29, O: 12/27 | MI: 23/10, O: 21/12 | MI: 20/52, O: 22/50 | MI: 7/8, O: 5/10 | MI: 4/6, O: 5/7 |
Diagnosis | -DDD -Grade I olisthesis | -Stenosis (MI/O: 23/20) -Olisthesis (MI/O: 14/15) -Postoperative instability (MI/O: 5/4) | -DDD (MI/O: 13/14) -Olisthesis (MI/O: 20/19) | -Olisthesis (grades I and II) -Recurrent prolapsed disc -Spinal stenosis -DDD | -Grade I degenerative olisthesis | -Spondylosis (MI/O: 5/6) -Olisthesis (MI/O: 4/6) -Spondylolysis (MI/O: 1/0) |
Outcomes | VAS, ODI, SF-36 Health Survey, operative time, EBL, LOS, duration of narcotic use, time to return to work, CPK (preoperative; days 1and 7, and 1.5, 3, and 6 months postoperative) | Operative time, blood loss, X-ray exposure time, complications, fusion rates, VAS, ODI—in overweight and obese patients | Operative time, EBL, LOS, anesthesia time, VAS, direct and indirect costs—in WC and non-WC patients | VAS, ODI, SF-36 Health Survey, NASS, time to return to full function, operative time, EBL, radiation exposure time, complications, fusion rates (Bridwell grading system) | VAS, ODI, quality of life (EuroQuol-5D), duration of narcotic use, time to return to work, direct and indirect costs, operative time, EBL, complications, LOS, fusion rates | Operative time, blood loss, LOS, pain scores, blood transfusion, time to ambulation, complications |
Author | Adogwa et al. [36] | Wang et al. [37] | Villavicencio et al. [14] | Shunwu et al. [38] | Wang et al. [37] | Peng et al. [39] |
Year of publication | 2010 | 2010 | 2010 | 2009 | 2010 | 2009 |
Study design | Retrospective | Prospective | Retrospective | Prospective | Prospective | Prospective |
Level of evidence | – | – | – | – | – | – |
Number of patients | 30 (MI = 15, O = 15) | 52 (MI = 25, O = 27) | 139 (MI = 76, O = 63) | 62 (MI = 32, O = 30) | 85 (MI = 42, O = 43) | 58 (MI = 29, O = 29) |
Follow-up (months) | 24 months | 27.5 (mean follow-up) | 37.5 (average follow-up) | 24 months (minimum follow-up) | 26.3 (mean follow-up) | 24 months (minimum follow-up) |
Mean age (years) | MI: 50.8, O: 49.7 | MI: 54.8, O: 56.2 | MI: 50.5, O: 58.9 | MI: 51.4, O: 52.0 | MI: 47.9, O: 53.2 | MI: 54.1, O: 52.5 |
Gender (m/f) | MI: 7/8, O: 5/10 | MI: 13/12, O: 15/12 | MI: 45/31, O: 38/25 | MI: 18/14, O: 14/16 | MI: 13/29, O: 16/27 | MI: 5/24, O: 5/24 |
Diagnosis | Grade I Olisthesis | -Recurrent disc herniation (MI/O: 7/8) -Lumbar canal stenosis(MI/O: 10/9) -Segmental instability (MI/O: 5/7) -Olisthesis < Grade II (MI/O: 3/3) | -DDD with/without disc herniation -Olisthesis -Stenosis at one or two spinal levels | -Discogenic low back pain (MI/O: 6/4) -Unilateral lumbar disc herniation (MI/O: 13/4) -Foraminal stenosis (MI/O: 3/8) -Separation of posterior ring apophysis (MI/O: 3/4) -Low-grade olisthesis (MI/O: 5/8) -Single-segment instability (MI/O: 2/2) | -Degenerative Olisthesis (MI/O: 24/22) -Isthmic Olisthesis (MI/O: 18/21) | -Grade I/II Olisthesis -DDD presenting with low back pain and radicular symptoms |
Outcomes | VAS, ODI, EuroQol-5D, occupational disability, narcotic use, time to return to work, operative time, EBL | VAS, ODI, operative time, blood loss, radiation exposure time, complications, fusion rates | Operative time, EBL, LOS, VAS, patient satisfaction, MacNab’s criteria fusion rates, complications (major, minor) | Operative time, blood loss, total transfusion volume, LOS, time to ambulation, complications, serum CK, VAS, ODI, fusion rates | Operative time, transfusion volume, X-ray exposure times, LOS, complications, VAS, ODI, fusion rates | NASS, ODI, VAS, SF-36, operative time, blood loss, radiation exposure time, time to ambulation, narcotic use, fusion rates (Bridwell criteria) |
Author | Dhall et al. [40] | Schizas et al. [41] | ||||
Year of publication | 2008 | 2008 | ||||
Study design | Retrospective | Prospective | ||||
Level of evidence | – | – | ||||
Number of patients | 42 (MI = 21, O = 21) | 36 (MI = 18, O = 18) | ||||
Follow-up (months) | 24 months (MI), 34 months (O) (mean follow-up) | 22 months (MI), 24 months (O) (average follow-up) | ||||
Mean age (years) | MI: 53, O: 53 | MI: 45.5, O: 48.1 | ||||
Gender (m/f) | – | – | ||||
Diagnosis | -DDD (MI/O: 14/10) -Degenerative olisthesis (MI/O: 7/11) | -Isthmic Olisthesis (MI/O: 15/6) -Asymmetrical disc disease with foraminal stenosis (MI/O: 2/12) -Iatrogenic spondylosis (MI/O: 1/0) | ||||
Outcomes | Operative time, EBL, LOS, complications, fusion rates, mPS | Operative time, intraoperative and total blood loss, radiation exposure time, VAS and ODI scores, analgesia intake, fusion rates, complications, learning curve |
Author | MITLIF | OTLIF | ||||
---|---|---|---|---|---|---|
Mean | SD | Nr. of Pat. | Mean | SD | Nr. of Pat. | |
Zhang et al. 2017 [14] | 146 | ± 15 | 48 | 136 | ± 25 | 59 |
Yang et al. 2017 [15] | 179.0 | ± 20.7 | 21 | 141.8 | ± 18.8 | 20 |
Tschugg et al. 2017 [16] | 173.4 | ± 71 | 19 | 208.8 | ± 86 | 48 |
Kulkarni et al. 2016 [17] | 204 | ± 32.4 | 36 | 177.6 | ± 34.2 | 25 |
Hey et al. 2015 [18] | 366.3 | – | 25 | 252.5 | – | 25 |
Wong et al. 2014 [22] | 123 | – | 144 | 225 | – | 54 |
Sulaiman et al. 2014 [13] | 375 | ± 14 | 57 | 161 | ± 7.6 | 11 |
Singh et al. 2014 [23] | 115.8 | ± 28.2 | 33 | 186.0 | ± 31.0 | 33 |
Gu et al. 2014 [24] | 195.5 | ± 28.0 | 44 | 186.6 | ± 23.4 | 38 |
Brodano et al. 2013 [25] | 144 | – | 30 | 102 | – | 34 |
Seng et al. 2013 [26] | 185 | ± 8.7 | 40 | 166 | ± 7 | 40 |
Cheng et al. 2013 [27] | 244.6 | ± 73.0 | 50 | 278.8 | ± 14.5 | 25 |
Parker et al. 2013 [30] | 274 | – | 50 | 229 | – | 50 |
Adogwa et al. 2012 [31] | 235 | ± 88.36 | 14 | 211 | ± 43.23 | 7 |
Wang et al. 2012 [32] | 127 | ± 25 | 42 | 168 | ± 37 | 39 |
Pelton et al. 2012 [33] | 113 | ± 32.30 | 33 | 184.5 | ± 33.94 | 33 |
Lee et al. 2012 [6] | 166.4 | ± 52.1 | 72 | 181.8 | ± 45.4 | 72 |
Parker et al. 2012 [34] | 300 | – | 15 | 210 | – | 15 |
Lau et al., 2010 [35] | 389.67 | – | 10 | 365.30 | – | 12 |
Adogwa et al. 2010 [36] | 300 | – | 15 | 210 | – | 15 |
Wang et al. 2010 [37] | 139 | ± 27 | 25 | 143 | ± 35 | 27 |
Villavicen et al. 2010 [42] | 222.5 | ± 67.5 | 76 | 214.9 | ± 60 | 63 |
Shunwu et al. 2009 [38] | 159.2 | ± 21.7 | 32 | 142.8 | ± 22.5 | 30 |
Wang et al. 2010 [37] | 156 | ± 32 | 42 | 145 | ± 27 | 43 |
Peng et al. 2009 [39] | 216.4 | – | 29 | 170.5 | – | 29 |
Dhall et al. 2008 [26] | 199 | – | 21 | 237 | – | 21 |
Schizas et al. 2008 [41] | 348 | – | 18 | 312 | – | 18 |
Author | MITLIF | OTLIF | ||||
---|---|---|---|---|---|---|
Mean | SD | Nr. of Pat. | Mean | SD | Nr. of Pat. | |
Zhang et al. 2017 [14] | 602 | ± 251 | 48 | 742 | ± 275 | 59 |
Yang et al. 2017 [15] | 355.3 | ± 75.0 | 21 | 538.6 | ± 129.5 | 20 |
Tschugg et al. 2017 [16] | 110.5 | ± 205 | 19 | 472.3 | ± 555 | 48 |
Kulkarni et al. 2016 [17] | 111.81 | – | 36 | 358.8 | – | 25 |
Hey et al., 2015 [18] | 362.5 | – | 25 | 267.5 | – | 25 |
Terman et al. 2014 [21] | 100 | – | 53 | 450 | – | 21 |
Wong et al. 2014 [22] | 115 | – | 144 | 485 | – | 54 |
Sulaiman et al. 2014 [13] | 95 | ± 20 | 57 | 786 | ± 107 | 11 |
Singh et al. 2014 [23] | 124.4 | ± 92.0 | 33 | 380.3 | ± 191.2 | 33 |
Gu et al. 2014 [24] | 248.4 | ± 94.3 | 44 | 576.3 | ± 176.2 | 38 |
Brodano et al. 2013 [25] | 230 | – | 30 | 620 | – | 34 |
Seng et al. 2013 [26] | 127.3 | ± 45.7 | 40 | 405 | ± 80 | 40 |
Cheng et al. 2013 [27] | 392.5 | ± 284.0 | 50 | 535.5 | ± 324.0 | 25 |
Lau et al. 2013 [28] | 168.6 | ± 162.1 | 78 | 661.0 | ± 561.3 | 49 |
Parker et al. 2013 [30] | 200 | – | 50 | 350 | – | 50 |
Adogwa et al. 2012 [31] | 220 | ± 207.32 | 14 | 280 | ± 219.65 | 7 |
Wang et al. 2012 [32] | 326 | ± 122 | 42 | 835 | ± 247 | 39 |
Pelton et al. 2012 [33] | 125.5 | ± 82.425 | 33 | 271 | ± 84.915 | 33 |
Lee et al. 2012 [6] | 50.6 | ± 161.0 | 72 | 976.3 | ± 760.8 | 72 |
Parker et al. 2012 [34] | 200 | – | 15 | 295 | – | 15 |
Lau et al. 2010 [35] | 466.67 | – | 10 | 565,63 | – | 12 |
Adogwa et al. 2010 [36] | 200 | – | 15 | 295 | – | 15 |
Wang et al. 2010 [37] | 316 | ± 96 | 25 | 799 | ± 208 | 27 |
Villavicen et al. 2010 [42] | 163.0 | ± 131.2 | 76 | 366.8 | ± 298.2 | 63 |
Shunwu et al. 2009 [38] | 578 | ± 138.8 | 32 | 711.4 | ± 157.3 | 30 |
Wang et al. 2010 [37] | 303 | ± 101 | 42 | 831 | ± 210 | 43 |
Peng et al. 2009 [39] | 150 | – | 29 | 681 | – | 29 |
Dhall et al. 2008 [40] | 194 | – | 21 | 505 | – | 21 |
Schizas et al. 2008 [41] | 551 | – | 18 | 1438 | – | 18 |
Author | MITLIF | OTLIF | ||||
---|---|---|---|---|---|---|
Mean | SD | Nr. of Pat. | Mean | SD | Nr. of Pat. | |
Zhang et al. 2017 [14] | 7.9 | ± 2.8 | 48 | 10.1 | ± 3.2 | 59 |
Tschugg et al. 2017 [16] | 13.7 | ± 5 | 19 | 19.1 | ± 12 | 48 |
Kulkarni et al. 2016 [17] | 4.11 | ± 1.8 | 36 | 5.84 | ± 2.249 | 25 |
Hey et al. 2015 [18] | 10.0 | – | 25 | 7.7 | – | 25 |
Terman et al. 2014 [21] | 2 | – | 53 | 3 | – | 21 |
Wong et al. 2014 [22] | 2.75 | – | 144 | 4.40 | – | 54 |
Sulaiman et al. 2014 [13] | 3.6 | ± 1 | 57 | 3.2 | ± 0.2 | 11 |
Singh et al. 2014 [23] | 2.3 | ± 1.2 | 33 | 2.9 | ± 1.1 | 33 |
Gu et al. 2014 [24] | 9.3 | ± 3.7 | 44 | 12.1 | ± 3.6 | 38 |
Brodano et al. 2013 [25] | 4.1 | – | 30 | 7.4 | – | 34 |
Seng et al. 2013 [26] | 3.6 | ± 0.3 | 40 | 5.9 | ± 0.4 | 40 |
Cheng et al. 2013 [27] | 4.8 | ± 1.8 | 50 | 6.05 | ± 1.8 | 25 |
Lau et al. 2013 [28] | 3.1 | ± 1.7 | 78 | 4.7 | ± 2.1 | 49 |
Parker et al. 2013 [30] | 3 | – | 50 | 4 | – | 50 |
Adogwa et al. 2012 [31] | 3 | – | 14 | 4 | – | 7 |
Pelton et al. 2012 [33] | 2 | ± 0.713 | 33 | 3 | ± 1.1 | 33 |
Lee et al. 2012 [6] | 3.2 | ± 2.9 | 72 | 6.8 | ± 3.4 | 72 |
Parker et al. 2012 [34] | 3.0 | – | 15 | 5.0 | – | 15 |
Lau et al. 2010 [35] | 5.00 | – | 10 | 6.17 | – | 12 |
Villavicen et al. 2010 [42] | 3.0 | ± 2.3 | 76 | 4.2 | ± 3.5 | 63 |
Shunwu et al. 2009 [38] | 9.3 | ± 2.6 | 32 | 12.50 | ± 1.8 | 30 |
Wang et al. 2010 [37] | 10.6 | ± 2.5 | 42 | 14.6 | ± 3.8 | 43 |
Peng et al. 2009 [39] | 4.0 | – | 29 | 6.7 | – | 29 |
Dhall et al. 2008 [40] | 3 | – | 21 | 5.5 | – | 21 |
Schizas et al. 2008 [41] | 6.1 | – | 18 | 8.2 | – | 18 |
Author | MITLIF | OTLIF | ||
---|---|---|---|---|
Number of complications | Number of patients | Number of complications | Number of patients | |
c et al. 2017 [15] | 2 | 21 | 1 | 20 |
Hey et al. 2015 [18] | 8 | 25 | 2 | 25 |
Adogwa et al. 2015 [19] | 5 | 40 | 12 | 108 |
Terman et al. 2014 [21] | 9 | 53 | 11 | 21 |
Sulaiman et al. 2014 [13] | 4 | 57 | 2 | 11 |
Gu et al. 2014 [24] | 5 | 44 | 4 | 38 |
Brodano et al. 2013 [25] | 1 | 30 | 2 | 34 |
Seng et al. 2013 [26] | 2 | 40 | 4 | 40 |
Lau et al. 2013 [28] | 9 | 78 | 14 | 49 |
Adogwa et al. 2012 [31] | 0 | 14 | 2 | 7 |
Wang et al. 2012 [32] | 4 | 42 | 7 | 39 |
Parker et al. 2012 [34] | 0 | 15 | 0 | 15 |
Lau et al. 2010 [35] | 4 | 10 | 1 | 12 |
Adogwa et al. 2010 [36] | 0 | 15 | 0 | 15 |
Shunwu et al. 2009 [38] | 6 | 32 | 5 | 30 |
Peng et al. 2009 [39] | 2 | 29 | 4 | 29 |
Dhall et al. 2008 [40] | 3 | 21 | 2 | 21 |
Author | MITLIF | OTLIF | ||||
---|---|---|---|---|---|---|
Mean | SD | Number of patients | Mean | SD | Number of patients | |
Gu et al. 2014 [24] | 45.3 | ± 11.7 | 44 | 28.9 | ± 8.2 | 38 |
Seng et al. 2013 [26] | 55.2 | ± 11.3 | 40 | 16.4 | ± 2.1 | 40 |
Wang et al. 2012 | 46 | ± 21 | 42 | 24 | ± 8 | 39 |
Lee et al. 2012 [6] | 49.0 | ± 33.9 | 72 | 17.6 | ± 20.0 | 72 |
Wang et al. 2010 [37] | 73 | ± 21 | 25 | 39 | ± 16 | 27 |
Wang et al. 2010 [37] | 84 | ± 21 | 42 | 37 | ± 19 | 43 |
Peng et al. 2009 [39] | 105.5 | – | 29 | 35.2 | – | 29 |
Author | MITLIF | OTLIF | ||||
---|---|---|---|---|---|---|
Nr. of Pat. | Preoperative (mean ± SD) | Last follow-up (mean ± SD) | Nr. of Pat. | Preoperative (mean ± SD) | Last follow-up (mean ± SD) | |
Yang et al. 2017 [15] | 21 | 5.8 ± 0.9 | 1.0 ± 0.9 | 20 | 5.6 ± 0.8 | 1.2 ± 1.2 |
Adogwa et al. 2015 [19] | 40 | 6.97 ± 2.49 | 4.55 ± 3.81 | 108 | 7.0 ± 2.44 | 4.67 ± 3.67 |
Terman et al. 2014 [21] | 53 | 7.1 (−) | 4.7 (−) | 21 | 7.1 (−) | 4.3 (−) |
Wong et al. 2014 [22] | 144 | 6.37 (−) | 1.05 (−) | 54 | 6.72 (−) | 1.70 (−) |
Sulaiman et al. 2014 [13] | 57 | 7.3 (−) | 3.2 (−) | 11 | 7.3 (−) | 5.1 (−) |
Gu et al. 2014 [24] | 44 | 7.3 ± 1.2 | 1.9 ± 0.7 | 38 | 7.4 ± 1.0 | 1.8 ± 0.6 |
Brodano et al. 2013 [25] | 30 | 7.8 ± 1.4 | 2.3 ± 1.3 | 34 | 8.1 ± 1.5 | 2.6 ± 1.2 |
Seng et al. 2013 [26] | 40 | 5.6 ± 3.3 | 1.3 ± 0.4 | 40 | 6.2 ± 2.7 | 0.9 ± 0.3 |
Cheng et al. 2013 [27] | 50 | 7.1 ± 0.7 | 2.9 ± 0.3 | 25 | 7.6 ± 0.5 | 3.5 ± 0.5 |
Rodriguez-Vela et al. 2013 [29] | 21 | 7.04 ± 1.12 | 3.381 ± 2.69 | 20 | 7.19 ± 2.21 | 4.611 ± 3.12 |
Parker et al. 2013 [30] | 50 | 8.1 ± 2.6 | 3.3 ± 2.9 | 50 | 8.5 ± 2.2 | 3.6 ± 2.8 |
Adogwa et al. 2012 [31] | 14 | 6.80 ± 2.40 | – | 7 | 6.14 ± 1.67 | 3.14 (−) |
Wang et al. 2012 [32] | 42 | 6.3 ± 2.5 | 1.3 ± 0.6 | 39 | 6.0 ± 2.1 | 1.5 ± 0.5 |
Lee et al. 2012 [6] | 72 | 6.3 ± 2.9 | 2.3 ± 3.0 | 72 | 6.3 ± 2.9 | 2.4 ± 2.7 |
Parker et al. 2012 [34] | 15 | 8.4 ± 1.7 | 5.5 ± 2.6 | 15 | 9.3 ± 0.9 | 4.7 ± 3.2 |
Adogwa et al. 2010 [36] | 15 | 8.4 ± 1.7 | 5.5 ± 2.6 | 15 | 9.3 ± 0.9 | 4.7 ± 3.2 |
Wang et al. 2010 [37] | 25 | 7.1 ± 2.4 | 1.3 ± 0.5 | 27 | 6.9 ± 1.7 | 1.5 ± 0.4 |
Villavicen et al. 2010 [42] | 76 | 7.4 (−) | 3.4 (−) | 63 | 8.0 (−) | 3.2 (−) |
Shunwu et al. 2009 [38] | 32 | 6.8 ± 1.2 | 2.3 ± 1.5 | 30 | 6.8 ± 1.4 | 3.2 ± 1.2 |
Wang et al. 2010 [37] | 42 | 7.2 ± 2.1 | 0.92 ± 0.5 | 43 | 7.4 ± 1.6 | 1.1 ± 0.6 |
Peng et al. 2009 [39] | 29 | 6 (−) | 1 (−) | 29 | 6.5 (−) | 1.2 (−) |
Schizas et al. 2008 [41] | 18 | 7.7 (−) | 3.5 (−) | 18 | 5.0 (−) | 2.8 (−) |
Author | MITLIF | OTLIF | ||||
---|---|---|---|---|---|---|
Nr. of Pat. | Preoperative (mean ± SD) | Last follow-up (mean ± SD) | Nr. of Pat. | Preoperative (mean ± SD) | Last follow-up (mean ± SD) | |
Yang et al. 2017 [15] | 21 | 5.2 ± 1.3 | 0.6 ± 0.7 | 20 | 4.9 ± 1.8 | 0.9 ± 0.9 |
Adogwa et al. 2015 [19] | 40 | 7.07 ± 3.00 | 3.3 ± 4.53 | 108 | 6.58 ± 2.98 | 3.91 ± 4.10 |
Terman et al. 2014 [21] | 53 | 7.1 (−) | 4.7 (−) | 21 | 7.1 (−) | 4.3 (−) |
Wong et al. 2014 [22] | 144 | 8.9 (−) | 1.15 (−) | 54 | 8.82 (−) | 1.30 (−) |
Sulaiman et al. 2014 [13] | 57 | 7.3 (−) | 3.2 (−) | 11 | 7.3 (−) | 5.1 (−) |
Gu et al. 2014 [24] | 44 | 7.6 ± 0.9 | 1.7 ± 0.6 | 38 | 7.7 ± 0.9 | 1.8 ± 0.7 |
Brodano et al. 2013 [25] | 30 | 7.8 ± 1.4 | 2.3 ± 1.3 | 34 | 8.1 ± 1.5 | 2.6 ± 1.2 |
Seng et al. 2013 [26] | 40 | 5.9 ± 2.8 | 0.8 ± 0.4 | 40 | 5.7 ± 3.2 | 1.0 ± 0.3 |
Cheng et al. 2013 [27] | 50 | 7.1 ± 0.7 | 2.9 ± 0.3 | 25 | 7.6 ± 0.5 | 3.5 ± 0.5 |
Rodriguez-Vela et al. 2013 [29] | 21 | 7.31 ± 2.05 | 2.381 ± 2.65 | 20 | 7.53 ± 1.23 | 3.138 ± 2.69 |
Parker et al. 2013 [30] | 50 | 6.5 ± 3.6 | 3.0 ± 3.0 | 50 | 6.9 ± 3.3 | 2.7 ± 2.6 |
Adogwa et al. 2012 [31] | 14 | 5.99 ± 2.61 | – | 7 | 6.07 ± 2.69 | 1.58 (−) |
Lee et al. 2012 [6] | 72 | 5.8 ± 3.3 | 1.6 ± 2.7 | 72 | 6.2 ± 3.1 | 2.0 ± 2.8 |
Parker et al. 2012 [34] | 15 | 8.5 ± 1.3 | 5.5 ± 2.9 | 15 | 8.2 ± 1.3 | 3.5 ± 3.5 |
Adogwa et al. 2010 [36] | 15 | 8.5 ± 1.3 | 5.5 ± 2.9 | 15 | 8.2 ± 1.3 | 3.5 ± 3.5 |
Wang et al. 2010 [37] | 25 | – | 1.0 ± 0.3 | 27 | – | 1.3 ± 0.4 |
Villavicen et al. 2010 [42] | 76 | 7.4 (−) | 3.4 (−) | 63 | 8.0 (−) | 3.2 (−) |
Shunwu et al. 2009 [38] | 32 | 6.8 ± 1.2 | 2.3 ± 1.5 | 30 | 6.8 ± 1.4 | 3.2 ± 1.2 |
Peng et al. 2009 [39] | 29 | 7 (−) | 1 (−) | 29 | 6.5 (−) | 1.1 (−) |
Schizas et al. 2008 [41] | 18 | 7.7 (−) | 3.5 (−) | 18 | 5.0 (−) | 2.8 (−) |
Author | MITLIF | OTLIF | ||||
---|---|---|---|---|---|---|
Nr. of Pat. | Preoperative (mean ± SD) | Last follow-up (mean ± SD) | Nr. of Pat. | Preoperative (mean ± SD) | Last follow-up (mean ± SD) | |
Yang et al. 2017 [15] | 21 | 43.5 ± 15.1 | 12.0 ± 6.4 | 20 | 44.2 ± 14.3 | 13.5 ± 6.5 |
Adogwa et al. 2015 [19] | 40 | 50.18 ± 16.74 | 38.57 ± 25.52 | 108 | 49.15 ± 15.21 | 34.27 ± 22.07 |
Terman et al. 2014 [21] | 53 | 59 (−) | 44 (−) | 21 | 58 (−) | 45 (−) |
Wong et al. 2014 [22] | 144 | 52.8 (−) | 18 (−) | 54 | 51.2 (−) | 21 (−) |
Sulaiman et al. 2014 [13] | 57 | 53.7 (−) | 26.4 (−) | 11 | 57.8 (−) | 46.1 (−) |
Gu et al. 2014 [24] | 44 | 43.7 ± 4.3 | 16.5 ± 2.0 | 38 | 44.3 ± 5.2 | 15.9 ± 1.9 |
Brodano et al. 2013 [25] | 30 | 42 ± 6.2 | 10 ± 6.6 | 34 | 46 ± 7.1 | 12 ± 5.8 |
Seng et al. 2013 [26] | 40 | 41.3 ± 20.1 | 13.6 ± 2.8 | 40 | 42.1 ± 16.3 | 12.3 ± 1.9 |
Rodriguez-Vela et al. 2013 [29] | 21 | 28.85 ± 5.52 | 12.09 ± 7.59 | 20 | 27.19 ± 8.19 | 18.10 ± 12.45 |
Parker et al. 2013 [30] | 50 | 32.3 ± 6.7 | 11.0 ± 9.4 | 50 | 34.3 ± 7.9 | 15.6 ± 10.3 |
Adogwa et al. 2012 [31] | 14 | 20.50 ± 7.76 | – | 7 | 22.57 ± 9.32 | 11.93 (−) |
Wang et al. 2012 [32] | 42 | 41.1 ± 10.3 | 18.2 ± 5.9 | 39 | 40.2 | 17.4 ± 7.1 |
Lee et al. 2012 [6] | 72 | 48.1 ± 18.8 | 21.4 ± 20.9 | 72 | 44.4 ± 18.0 | 20.7 ± 16.5 |
Parker et al. 2012 [34] | 15 | 36.9 ± 6.3 | 15.7 ± 8.9 | 15 | 34.3 ± 11.5 | 17.1 ± 9.5 |
Adogwa et al. 2010 [36] | 15 | 36.9 ± 6.3 | 15.7 ± 8.9 | 15 | 34.3 ± 11.5 | 17.1 ± 9.5 |
Wang et al. 2010 [37] | 25 | 39.7 ± 10.1 | 12.4 ± 3.6 | 27 | 37.9 ± 8.2 | 11.5 ± 4.2 |
Shunwu et al. 2009 [38] | 32 | 49.7 ± 11.8 | 24.7 ± 10.1 | 30 | 52 ± 12 | 27.2 ± 8.4 |
Wang et al. 2010 [37] | 42 | 41.2 ± 6.6 | 10.8 ± 3.3 | 43 | 38.5 ± 7.4 | 12.2 ± 3.9 |
Peng et al. 2009 [39] | 29 | 45.2 ± 3.5 | 16.2 ± 3.4 | 29 | 47.7 ± 3.2 | 17.5 ± 3.8 |
Schizas et al. 2008 [41] | 18 | 55 (−) | 33 (−) | 18 | 53 (−) | 26 (−) |